Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor
6/30/2014 8:35:55 AM
MALVERN,Pa.--(BUSINESS WIRE)--Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors. While benign, many patients elect to have SK treated either because the lesions have become irritated or are cosmetically concerning.
Help employers find you! Check out all the jobs and post your resume.
comments powered by